+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Enzyme Replacement Therapy Market (2022-2027) by Therapeutic Condition, Enzyme Type, End-User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon


  • 190 Pages
  • June 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5635953

Key players who have been currently dominating the market are Pfizer Inc, Takeda Pharmaceutical Company Ltd, and Johnson & Johnson Services Inc among others

The Global Enzyme Replacement Therapy Market is estimated to be USD 1.46 Bn in 2022 and is expected to reach USD 2.47 Bn by 2027, growing at a CAGR of 11.06%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Enzyme Replacement Therapy Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

The Global Enzyme Replacement Therapy Market is segmented based on Therapeutic Condition, Enzyme Type, End-User, and Geography.
  • By Therapeutic Condition, the market is classified into Fabry Disease, Gaucher Disease, Mucopolysaccharidosis (MPS), Pompe Disease, and Severe combined immunodeficiency (SCID).
  • By Enzyme Type, the market is classified into Agalsidase Beta, Alglucosidase Alfa, Galsulfase, Idursulfase, Imiglucerase, Laronidase, Pancreatic Enzymes, Pegademase, Taliglucerase, and Velaglucerase Alfa.
  • By End-User, the market is classified into Hospitals and Infusion Centers.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Amicus Therapeutics, Generium, Pfizer Inc., Shire Plc, Sigma Aldrich, Sigma-Tau Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd, Teijin Pharma Ltd, Ultragenyx Pharmaceutical Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Enzyme Replacement Therapy Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The analyst analyses the Global Enzyme Replacement Therapy Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Enzyme Replacement Therapy Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Enzyme Replacement Therapy Market

What is the estimated value of the Global Enzyme Replacement Therapy Market?

The Global Enzyme Replacement Therapy Market was estimated to be valued at $1.46 Billion in 2022.

What is the growth rate of the Global Enzyme Replacement Therapy Market?

The growth rate of the Global Enzyme Replacement Therapy Market is 11.0%, with an estimated value of $2.47 Billion by 2027.

What is the forecasted size of the Global Enzyme Replacement Therapy Market?

The Global Enzyme Replacement Therapy Market is estimated to be worth $2.47 Billion by 2027.

Who are the key companies in the Global Enzyme Replacement Therapy Market?

Key companies in the Global Enzyme Replacement Therapy Market include Abbott Laboratories, AbbVie Inc., Actelion, Alexion Pharmaceuticals Inc., Allergan plc, Amicus Therapeutics, BioMarin Pharmaceutical Inc., CANBridge Pharmaceuticals, Clinigen Group and Generium.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increasing Awareness about Rare Diseases
4.1.2 Availability of Enzyme Therapy with Ease of Guidelines for The Approval Purpose
4.1.3 Government Support in Treatment Initiatives
4.2 Restraints
4.2.1 High Cost of The Treatment
4.2.2 Low Prevalence of Rare or Orphan Diseases
4.3 Opportunities
4.3.1 Advent of Orphan Disease Management
4.3.2 High Investments In R&D To Treat Rare Diseases
4.4 Challenges
4.4.1 Side Effects of The Treatment
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Enzyme Replacement Therapy Market, By Therapeutic Condition
6.1 Introduction
6.2 Fabry Disease
6.3 Gaucher Disease
6.4 Mucopolysaccharidosis (MPS)
6.5 Pompe Disease
6.6 Severe combined immunodeficiency (SCID)
7 Global Enzyme Replacement Therapy Market, By Enzyme Type
7.1 Introduction
7.2 Agalsidase Beta
7.3 Alglucosidase Alfa
7.4 Galsulfase
7.5 Idursulfase
7.6 Imiglucerase
7.7 Laronidase
7.8 Pancreatic Enzymes
7.9 Pegademase
7.10 Taliglucerase
7.11 Velaglucerase Alfa
8 Global Enzyme Replacement Therapy Market, By End-User
8.1 Introduction
8.2 Hospitals
8.3 Infusion Centers
9 Americas’ Enzyme Replacement Therapy Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas
10 Europe’s Enzyme Replacement Therapy Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Italy
10.9 Netherlands
10.10 Norway
10.11 Poland
10.12 Russia
10.13 Spain
10.14 Sweden
10.15 Switzerland
10.16 United Kingdom
10.17 Rest of Europe
11 Middle East and Africa’s Enzyme Replacement Therapy Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Qatar
11.5 Saudi Arabia
11.6 South Africa
11.7 United Arab Emirates
11.8 Rest of MEA
12 APAC’s Enzyme Replacement Therapy Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific
13 Competitive Landscape
13.1 Competitive Quadrant
13.2 Market Share Analysis
13.3 Strategic Initiatives
13.3.1 M&A and Investments
13.3.2 Partnerships and Collaborations
13.3.3 Product Developments and Improvements
14 Company Profiles
14.1 Abbott Laboratories
14.2 AbbVie Inc.
14.3 Actelion
14.4 Alexion Pharmaceuticals Inc.
14.5 Allergan plc
14.6 Amicus Therapeutics
14.7 BioMarin Pharmaceutical Inc.
14.8 CANBridge Pharmaceuticals
14.9 Clinigen Group
14.10 Generium
14.11 Horizon Pharma Public Limited Company
14.12 Menarini
14.13 Pfizer Inc.
14.14 Protalix Biotherapeutics
14.15 Sanofi SA
14.16 Shire Plc
14.17 Sigma Aldrich
14.18 Sigma-Tau Pharmaceuticals Inc.
14.19 Takeda Pharmaceutical Company Ltd
14.20 Teijin Pharma Ltd
14.21 Ultragenyx Pharmaceutical Inc.
15 Appendix
15.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Actelion
  • Alexion Pharmaceuticals Inc.
  • Allergan plc
  • Amicus Therapeutics
  • BioMarin Pharmaceutical Inc.
  • CANBridge Pharmaceuticals
  • Clinigen Group
  • Generium
  • Horizon Pharma Public Ltd. Company
  • Menarini
  • Pfizer Inc.
  • Protalix Biotherapeutics
  • Sanofi SA
  • Shire Plc
  • Sigma Aldrich
  • Sigma-Tau Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Teijin Pharma Ltd.
  • Ultragenyx Pharmaceutical Inc.